Journal article icon

Journal article

Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours

Abstract:

Background: Tumour cells with BRCA1/2 gene mutations demonstrate increased sensitivity to platinum and poly (ADP-ribose) polymerase (PARP) inhibitors. 6-mercaptopurine (6MP) was found to selectively kill BRCA-defective cells in a xenograft model as effectively as the PARP inhibitor AG014699, even after these cells acquired resistance to a PARP inhibitor or cisplatin.
Methods: This phase II single-arm trial investigated the activity of 6MP 55–75 ... Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Sub department:
Centre for Statistics in Medicine
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Sub department:
Botnar Research Centre
Oxford college:
All Souls College
Role:
Author
ORCID:
0000-0002-5172-512X
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Role:
Author
More from this funder
Name:
Cancer Research UK
Grant:
C5527/A16895
Publisher:
Springer Nature
Journal:
British Journal of Cancer More from this journal
Volume:
122
Issue:
4
Pages:
483-490
Publication date:
2019-12-19
Acceptance date:
2019-11-15
DOI:
EISSN:
1532-1827
ISSN:
0007-0920
Pmid:
31813938
Language:
English
Keywords:
Pubs id:
1077465
Local pid:
pubs:1077465
Deposit date:
2020-03-09

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP